Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics, Genentech

Premium
CombiMatrix Molecular Diagnostics this week launched its HerScan test for breast cancer. HerScan is an array comparative hybridization-based assay designed to detect amplification of the HER2 gene in early breast cancer. The test also provides clinicians with a complete profile of a patient's tumor genome, CMDX said.
 
The College of American Pathologists and the American Society of Clinical Oncology have recommended that HER2 status be determined in all invasive breast cancers as a prognostic marker for which patients are most likely to benefit from Genentech’s breast cancer drug Herceptin.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.